Capecitabine as Salvage Treatment for Lymphoepithelioma-Like Carcinoma of Lung  by Ho, James C. et al.
BRIEF REPORT
Capecitabine as Salvage Treatment for
Lymphoepithelioma-Like Carcinoma of Lung
James C. Ho, MD, FRCP, David C. Lam, MBBS, PhD, MRCP, Matthew K. Wong, MBBS, MRCP,
Bing Lam, FRCP, Mary S. Ip, MD, FRCP, and Wah K. Lam, MD, FRCP
Abstract: Lymphoepithelioma-like carcinoma (LELC) of lung has
previously demonstrated good clinical response to 5-fluorouracil
containing chemotherapy regimen, similar to the observation in
undifferentiated nasopharyngeal carcinoma. Capecitabine, which is
converted into active 5-fluorouracil within tumor cells, has been
found effective in colorectal, breast, and recently nasopharyngeal
carcinomas. We report our experience in five patients with advanced
or metastatic LELC of lung who were treated with single agent
capecitabine as salvage chemotherapy. The finding of disease control in
three of five patients, especially with exceptionally durable stable
disease (14.8 months) in one patient, suggests the potential clinical
activity of capecitabine in LELC of lung. Future studies on capecitab-
ine-containing chemotherapy regimens in LELC of lung are warranted.
Key Words: Lymphoepithelioma-like carcinoma, 5-Fluorouracil,
Capecitabine.
(J Thorac Oncol. 2009;4: 1174–1177)
Lymphoepithelioma-like carcinoma (LELC) of lung hasbeen a well-recognized special entity of non-small cell
lung cancer (NSCLC), with etiological link to Epstein-Barr
virus and histologically close resemblance to undifferentiated
nasopharyngeal carcinoma (NPC). The largest reports were
mainly ethnically Orientals from Southern China, Taiwan,
and Hong Kong.1 Because of its uncommon occurrence, there
have been no large-scale randomized controlled trials on the
optimal treatment options for advanced LELC of lung. Most
of the previous reports on options of chemotherapy treatment
were largely anecdotal. Nevertheless, there has been promis-
ing response to 5-fluorouracil (5-FU) and cisplatin combina-
tion chemotherapy as first-line treatment in advanced LELC
of lung, mimicking the clinical response in NPC.2,3 The use
of systemic chemotherapy in the salvage treatment of ad-
vanced disease has not been well reported. Capecitabine,
basically functioning as a prodrug of 5-FU, has been consid-
ered as a reasonable alternative treatment in malignancies that
are particularly responsive to 5-FU, like colon cancer and
NPC. Therefore, we conducted this retrospective study to
review our preliminary experience with the use of capecitab-
ine in treatment of advanced LELC of lung.
PATIENTS AND METHODS
Case Identification
This is a retrospective case series of patients with
pathologically confirmed advanced unresectable LELC of
lung who had received capecitabine (Xeloda, Roche Pharma-
ceuticals) as salvage chemotherapy in the Department of
Medicine at Queen Mary Hospital, a University-affiliated
teaching hospital in Hong Kong, since 2002. The eligible
cases were identified from our prospective clinical database
of all newly diagnosed lung cancers in Queen Mary Hospital,
as previously approved by our Institutional Review Board.
The diagnostic workup of primary LELC of lung has been
described previously.1,2,4 The classification of tumor staging
was based on tumor node metastasis staging system.5
Chemotherapy for LELC of Lung
Our institutional treatment protocol for primary LELC of
lung has been reported previously.1,2 The first-line chemother-
apy for advanced or metastatic primary LELC of lung involved
a combination of 5-FU (1000 mg/m2, days 1–4), leucovorin, and
cisplatin (100 mg/m2, day 1) (FLP) at 4-weekly interval for 4 to
6 cycles. On disease progression after first-line chemotherapy,
other chemotherapy regimens (containing paclitaxel, docetaxel,
or gemcitabine) that were commonly used in NSCLC would be
considered.6 Capecitabine, being converted to 5-FU within tu-
mor tissues, was considered as an alternative salvage treatment
especially with the recent preliminary experience in NPC.7 The
standard regimen of capecitabine was 1250mg/m2 orally twice
daily for 2 weeks followed by a 1-week rest period in 3-weekly
cycles, which would be stopped on disease progression or
intolerable adverse reactions.
Clinical Parameters
Demographic data (gender, age, and smoking status),
tumor characteristics (histologic evidence of LELC and TNM
staging), anticancer treatments (chemotherapy regimens and
their response and thoracic radiotherapy), and clinical out-
comes (time to progression and survival) were retrieved by
review of clinic charts and radiographs. Tumor assessment
was based on RECIST criteria8 as per institutional clinical
practice, after at least two cycles of chemotherapy treatment.
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RESULTS
Patient Characteristics
Since 2002, there were five patients with advanced or
metastatic primary LELC of lung who received capecitabine as
salvage chemotherapy in our institution (Table 1) in which they
were predominantly middle aged (56 8.7 years, mean SD),
women (75%), and nonsmokers (75%). All patients had histo-
logically confirmed LELC from lung tumor tissues, positive
in-situ hybridization for Epstein-Barr virus-encoded small nu-
clear RNA in tumor cells, and negative nasopharyngeal biopsy
to exclude NPC. Of particular note, one of the patients (case 5)
had history of early-stage NPC with curative radiotherapy 2
years before his presentation in which the diagnosis of primary
LELC of lung was based on radiologic pattern favoring lung
primary and absence of local recurrence in nasopharynx. All
patients presented with either locally advanced or metastatic
diseases (IIIA in two; IIIB in two; and IV in one patient).
Chemotherapy Treatment Before Capecitabine
The median number of chemotherapy regimens used
before salvage with capecitabine was 2 (range, 1–3). As per
institutional protocol, all five patients had received 5-FU
containing regimen (FLP) as first-line chemotherapy (median
6 cycles, range 4–6 cycles), attaining partial response in three
and stable disease in two patients. Newer generation chemo-
therapeutic agents as for other NSCLC (paclitaxel, gemcit-
abine, and docetaxel) were used in second- or third-line
settings (Table 1), with partial response in one patient on
gemcitabine monotherapy, stable disease in one patient on
paclitaxel/carboplatin and progressive disease in the rest.
Clinical Outcomes with Salvage Capecitabine
There were two patients (40%) with disease stabilization
and one patient (20%) with partial response while on capecit-
abine as salvage treatment (Table 2). The median duration of
starting capecitabine from the initiation of first-line chemother-
apy was 20.9 months (range, 6.7–63.1). The number of cycles of
capecitabine given ranged from 3 to 20 cycles, with one patient
still receiving treatment. Treatment was stopped in four patients
because of disease progression. Among the four patients with
disease progression, the median time to progression was 4.1
months (range: 1.6–14.8). There was no apparent relationship
between clinical response to capecitabine and previous best
overall response to first-line chemotherapy (FLP). Three patients
were still alive (median follow-up since start of capecitabine: 5
months; range: 5–5.5). For the two patients who died, the
survival times were 2.7 and 27months after start of capecitabine.
For the patient with long duration of disease stabilization, cape-
citabine was started in clinical stage IIIA disease (with ipsilateral
paratracheal lymphadenopathy) and her serial chest radiographs
(case 2) were shown in Figure 1. Computed tomography scans
of another patient (case 5) with disease control were shown in
Figure 2. The capecitabine treatment was well tolerated except
moderately severe degree of hand-foot syndrome in one patient
requiring short-term treatment with celecoxib (case 2) and pro-
longed but mild (grade 2) neutropenia requiring postponement
of treatment cycles in another patient (case 4). There were no
febrile neutropenia or treatment-related deaths.
DISCUSSION
From our preliminary experience of salvage treatment
with capecitabine in heavily pretreated patients with ad-
vanced LELC of lung, the treatment was in general well
tolerated and durable disease stabilization was observed in
one of five patients on such treatment, with the time to tumor
progression exceptionally prolonged (14.8 months). In addi-
tion, partial tumor response was attained with capecitabine in
another patient. The previous best overall tumor response to
5-FU containing chemotherapy (FLP) was not apparently
predictive of subsequent response to capecitabine.
Capecitabine, alone or in combination with other chemo-
therapy agents, has been approved for treatment of advanced
colorectal and breast cancers. The major advantages of capecit-
abine include oral route of administration and preferential action
on tumor cells. The latter is related to the significantly higher
level of thymidine phosphorylase, an enzyme responsible for the
final step in the conversion of capecitabine to 5-FU, within
malignant cells.9 Capecitabine and its intermediates are not
cytotoxic but only become active after conversion to 5-FU, thus
conferring a better safety profile than other fluoropyrimidines. In
fact, high tumor cell thymidine phosphorylase and low stromal
thymidine phosphorylase expression was associated with good
tumor response to combination of capecitabine and docetaxel in
a phase II trial in advanced NSCLC.10 Therefore, the high
intratumoral concentration and prolonged exposure to
5-FU may partly explain our observation of disease control
with capecitabine even among those who failed prior
5-FU-containing chemotherapy.
TABLE 1. Demography and Clinical Characteristics of Five Patients with Advanced Lymphoepithelioma-Like Carcinoma of
Lung Who Received Salvage Treatment with Capecitabine
Case Gender
Age at
Diagnosis
(yr)
Smoking
Status
Pack-Years
of Smoking
TNM Staging
at Diagnosis
Overall TNM
Staging at
Diagnosis
No. of Chemotherapy
Regimens Before
Capecitabine
Chemotherapy
Regimens Before
Capecitabine
Prior
Thoracic
Radiotherapy
1 Female 67 NS 0 T4N3M1 IV 2 FLP, G, Yes
2 Female 60 NS 0 T2N2M0 IIIA 2 FLP, DC Yes
3 Female 46 NS 0 T2N2M0 IIIA 2 FLP, GC Yes
4 Female 58 NS 0 T4N2M0 IIIB 3 FLP, TCb, GC Yes
5 Male 48 ES 15 T4N3M0 IIIB 1 FLP No
TNM, tumor node metastasis; NS, nonsmoker; ES, exsmoker; FLP, 5-fluorouracil, leucovorin, cisplatin; G, gemcitabine; DC, docetaxel/cisplatin; GC, gemcitabine/cisplatin; TCb,
paclitaxel/carboplatin.
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FIGURE 1. Chest radiographs of the index patient (case 2)
with durable disease stabilization to capecitabine treatment
for LELC of lung: (A) at baseline before capecitabine treat-
ment (right middle lobe tumor measured 4.5  3.5 cm); (B)
3 months after capecitabine treatment (right middle lobe
tumor measured 4  3.5 cm); and (C) 6 months after cape-
citabine treatment (right middle lobe tumor measured 4.2 
3.5 cm).
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Because the etiology and histologic features of primary
LELC of lung are similar to NPC, the previous reports on
systemic treatment for LELC of lung have mainly focused on
5-FU and cisplatin combination chemotherapy, with exception-
ally good clinical response (60–70% partial response rate).2,3 As
capecitabine essentially acts through its intracellular conversion
to 5-FU, it forms the rationale for its role in treatment of both
malignancies. In NPC, there has been only a single phase II
clinical trial of capecitabine in 17 patients with recurrent or
metastatic setting, achieving an overall response rate of 23.5%,
median survival 7.6 months, and estimated 1-year survival
35%.7 In a more recent retrospective review of using capecitab-
ine for 49 patients with recurrent or metastatic NPC, there was
an overall response rate of 37%, median time-to-progression of
5 months, and median survival of 14 months.11 For NSCLC,
there have been only a few clinical trials on the use of capecit-
abine in combination with docetaxel12,13 or irinotecan14 as sal-
vage treatment for advanced disease, suggesting favorable anti-
tumor activity. In the first-line setting, combination of
capecitabine with docetaxel has also demonstrated promising
activity in advanced NSCLC.15
From our knowledge, the clinical experience in using
capecitabine in treatment of primary LELC of lung has never
been reported before, partly related to its rarity. Although this
study is largely limited by its retrospective analysis, small
sample size, heterogeneous patient population and prior treat-
ment, and short duration of follow-up, the promising clinical
activity and good tolerability of capecitabine in previously
treated advanced LELC of lung should warrant future studies.
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FIGURE 2. Thoracic computed tomography scans of a pa-
tient (case 5) with tumor shrinkage while on capecitabine
treatment for LELC of lung: (A) before capecitabine treat-
ment (lingular tumor 2.3  3.5cm); (B) around 5 months
after capecitabine treatment (lingular tumor 1.7  2.0cm).
There was 32% reduction in the total sum of longest diame-
ters (including lingular mass, paratracheal lymph nodes, and
right hilar lymph node).
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